Adult risk groups for vaccine preventable respiratory infections: an overview of the UK environment
Author(s)
Type
Journal Article
Abstract
Introduction
Vaccine-preventable respiratory infections (VPRI) including those caused by Streptococcus pneumoniae, influenza, respiratory syncytial virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pose substantial challenges to health and social care systems. In the UK, routine adult respiratory vaccination programs are in place. The objective of this article is to review the current evidence on the impact of four seasonal VPRIs in adults risk group definitions and to explore the strengths and limitations of current recommendations, and to identify evidence gaps for further research.
Areas covered
Relevant evidence on UK data from surveillance systems, observational studies and publicly available government documents is collated and reviewed, as well as selected global data.
Expert opinion
Disparities exist between adult risk group categories for different respiratory vaccination programs as defined in the current vaccination guidance. The burden of multiple respiratory pathogens signifies importance of routine multi-pathogen testing with the need for a resilient and large-scale national surveillance system. Further understanding of epidemiological trends and disease burden will help guide decision-making and planning of targeted strategies for disease prevention and control. Addressing inequalities in disease burden and vaccine coverage particularly in clinical risk groups, and promoting equitable vaccine access remain a priority.
Vaccine-preventable respiratory infections (VPRI) including those caused by Streptococcus pneumoniae, influenza, respiratory syncytial virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pose substantial challenges to health and social care systems. In the UK, routine adult respiratory vaccination programs are in place. The objective of this article is to review the current evidence on the impact of four seasonal VPRIs in adults risk group definitions and to explore the strengths and limitations of current recommendations, and to identify evidence gaps for further research.
Areas covered
Relevant evidence on UK data from surveillance systems, observational studies and publicly available government documents is collated and reviewed, as well as selected global data.
Expert opinion
Disparities exist between adult risk group categories for different respiratory vaccination programs as defined in the current vaccination guidance. The burden of multiple respiratory pathogens signifies importance of routine multi-pathogen testing with the need for a resilient and large-scale national surveillance system. Further understanding of epidemiological trends and disease burden will help guide decision-making and planning of targeted strategies for disease prevention and control. Addressing inequalities in disease burden and vaccine coverage particularly in clinical risk groups, and promoting equitable vaccine access remain a priority.
Date Issued
2024-12
Date Acceptance
2024-11-06
Citation
Expert Review of Vaccines, 2024, 23 (1), pp.1052-1067
ISSN
1476-0584
Publisher
Taylor and Francis Group
Start Page
1052
End Page
1067
Journal / Book Title
Expert Review of Vaccines
Volume
23
Issue
1
Copyright Statement
© 2024 Pfizer Inc. Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
License URL
Identifier
https://www.tandfonline.com/doi/full/10.1080/14760584.2024.2428243#abstract
Subjects
Acute respiratory infection
CARE
CHILDREN
clinical risk groups
COVID-19
DEPRIVATION
ENGLAND
Immunology
influenza
INFLUENZA
INVASIVE PNEUMOCOCCAL DISEASE
Life Sciences & Biomedicine
MORTALITY
pneumococcal disease
respiratory syncytial virus
SARS-CoV-2
SARS-COV-2
Science & Technology
SYNCYTIAL VIRUS
vaccine uptake
vaccine-preventable respiratory infection
Publication Status
Published
Date Publish Online
2024-11-17